Access Pharmaceuticals Inc. (OTC:ACCP) At approximately 5:00pm EST, 6/23/09, StocksHaven Investments began the call conference scheduled with Director & CEO of Access Pharmaceuticals Inc., Mr. Jeffrey B. Davis, whom was also joined by Director & Consultant, Mr. David Luci. The basis of the interview was to provide an executive summary, along with their respective business [...]

BioElectronics Corporation (OTC:BIEL) BioElectronics is a company which is plagued by a poor financial balance sheet, unaudited filings and barely sustainable ongoing operations with its current expenses constantly exceeding revenues, however is it worth investing in? Here is a top-down unbiased analysis which tells all, investigating deeper into the lion’s den.

Nephros, Inc. (OTC: NEPH) A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with three pending FDA decisions. If you are an avid investor of pre-PDUFA companies, StocksHaven Investments highly [...]

Nuvo Research Inc. (TSE:NRI), (OTC:NRIFF) Nuvo Research Inc. has been red hot this past month and is expected to continue. StocksHaven Investments has identified Nuvo Research as its top candidate for undervalued biotech pre-PDUFA. With a current PPS below $1.00 CAD, and their product Pennsaid, a new and innovative treatment for osteoarthritis having expected net [...]

BioDelivery Sciences International (NASDAQ:BDSI) Continuing with the trend of pre-FDA decision BioPharma companies, StocksHaven Investments takes a closer look at BDSI which hopes its product Onsolis will strive past approval and make its way onto shelves world-wide.

With the World Health Organization (WHO) officially declaring the flu a pandemic of phase 6, one company looking to make waves is Hemispherx BioPharma (AMEX:HEB). Hemispherx has recently been in limbo awaiting FDA decision on the long-awaited treatment for Chronic Fatigue Syndrome (CFS), Ampligen. Ampligen, also known as poly I:poly C12U, is an experimental immunomodulatory [...]

Access Pharmaceuticals (OTC:ACCP), a once struggling and troubled company, Access has put these issues behind them and is emerging as one of the top undervalued players in the BioPharma industry. Not only does this company have products which target a large and extensive market, but they are also implementing solid fundamentals within business management principals. [...]

Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has identified several key points which have been raised recently, decyphering the fact from fiction. The following article has been submitted by an investor named, Nick DeCesare ————- After reviewing my own research, it is time to [...]

With the majority of the focus being placed on on the current pending FDA approval regarding (AMEX:HEB) Hemispherx’s Ampligen, StocksHaven Investments would like to shift the attention on the drug’s ability to help treat the potential outbreak of H5N1 (subtype of the Influenza A virus). Overview of H5N1 Also called “Influenza A (H5N1) virus” – [...]